|
|
|
|
LEADER |
03665nam a2200781Ia 4500 |
001 |
10-1177-20552173211069348 |
008 |
220420s2022 CNT 000 0 und d |
020 |
|
|
|a 20552173 (ISSN)
|
245 |
1 |
0 |
|a Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS
|
260 |
|
0 |
|b SAGE Publications Inc.
|c 2022
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1177/20552173211069348
|
520 |
3 |
|
|a Background: Serum neurofilament light chain (sNfL) levels are associated with relapses, MRI lesions, and brain volume in multiple sclerosis (MS). Objective: To explore the value of early serum neurofilament light (sNfL) measures in prognosticating 10-year regional brain volumes in MS. Methods: Patients with MS enrolled in the Comprehensive Longitudinal Investigations in MS at Brigham and Women's Hospital (CLIMB) study within five years of disease onset who had annual blood samples from years 1–10 (n = 91) were studied. sNfL was measured with a single molecule array (SIMOA) assay. We quantified global cortical thickness and normalized deep gray matter (DGM) volumes (fractions of the thalamus, caudate, putamen, and globus pallidus) from high-resolution 3 T MRI at 10 years. Correlations between yearly sNfL levels and 10-year MRI outcomes were assessed using linear regression models. Results: sNfL levels from years 1 and 2 were associated with 10-year thalamus fraction. Early sNfL levels were not associated with 10-year putamen, globus pallidus or caudate fractions. At 10 years, cortical thickness was not associated with early sNfL levels, but was weakly correlated with total DGM fraction. Conclusions: Early sNfL levels correlate with 10-year thalamic volume, supporting its role as a prognostic biomarker in MS. © The Author(s), 2022.
|
650 |
0 |
4 |
|a adult
|
650 |
0 |
4 |
|a Article
|
650 |
0 |
4 |
|a assay
|
650 |
0 |
4 |
|a beta1a interferon
|
650 |
0 |
4 |
|a beta1b interferon
|
650 |
0 |
4 |
|a biological marker
|
650 |
0 |
4 |
|a biomarker
|
650 |
0 |
4 |
|a brain size
|
650 |
0 |
4 |
|a caudate
|
650 |
0 |
4 |
|a caudate nucleus
|
650 |
0 |
4 |
|a cohort analysis
|
650 |
0 |
4 |
|a cortical thickness (brain)
|
650 |
0 |
4 |
|a deep gray matter
|
650 |
0 |
4 |
|a female
|
650 |
0 |
4 |
|a glatiramer
|
650 |
0 |
4 |
|a globus pallidus
|
650 |
0 |
4 |
|a gray matter volume
|
650 |
0 |
4 |
|a human
|
650 |
0 |
4 |
|a major clinical study
|
650 |
0 |
4 |
|a male
|
650 |
0 |
4 |
|a multiple sclerosis
|
650 |
0 |
4 |
|a neurofilament light chain
|
650 |
0 |
4 |
|a neuroimaging
|
650 |
0 |
4 |
|a nuclear magnetic resonance imaging
|
650 |
0 |
4 |
|a outcome assessment
|
650 |
0 |
4 |
|a prediction
|
650 |
0 |
4 |
|a prognostic assessment
|
650 |
0 |
4 |
|a protein
|
650 |
0 |
4 |
|a putamen
|
650 |
0 |
4 |
|a quality of life
|
650 |
0 |
4 |
|a relapse
|
650 |
0 |
4 |
|a serum neurofilament light (sNfL)
|
650 |
0 |
4 |
|a single molecule array assay
|
650 |
0 |
4 |
|a thalamic fraction
|
650 |
0 |
4 |
|a thalamus
|
650 |
0 |
4 |
|a unclassified drug
|
700 |
1 |
0 |
|a Anderson, M.
|e author
|
700 |
1 |
0 |
|a Bakshi, R.
|e author
|
700 |
1 |
0 |
|a Barro, C.
|e author
|
700 |
1 |
0 |
|a Chitnis, T.
|e author
|
700 |
1 |
0 |
|a Chu, R.
|e author
|
700 |
1 |
0 |
|a Glanz, B.I.
|e author
|
700 |
1 |
0 |
|a Granziera, C.
|e author
|
700 |
1 |
0 |
|a Healy, B.C.
|e author
|
700 |
1 |
0 |
|a Kappos, L.
|e author
|
700 |
1 |
0 |
|a Kropshofer, H.
|e author
|
700 |
1 |
0 |
|a Kuhle, J.
|e author
|
700 |
1 |
0 |
|a Leppert, D.
|e author
|
700 |
1 |
0 |
|a Lokhande, H.
|e author
|
700 |
1 |
0 |
|a Paul, A.
|e author
|
700 |
1 |
0 |
|a Polgar-Turcsanyi, M.
|e author
|
700 |
1 |
0 |
|a Rosso, M.
|e author
|
700 |
1 |
0 |
|a Saxena, S.
|e author
|
700 |
1 |
0 |
|a Tauhid, S.
|e author
|
700 |
1 |
0 |
|a Weiner, H.L.
|e author
|
773 |
|
|
|t Multiple Sclerosis Journal - Experimental, Translational and Clinical
|